Fasting Mimicking Diet During Neo-adjuvant Chemotherapy in Breast Cancer Patients: a Randomized Controlled Trial Study

Overview

Journal Front Nutr

Specialty Nutritional Sciences

Date 2024 Dec 20

PMID 39703333

Authors

Alireza Bahrami

Shirin Haghighi

Mona Malekzadeh Moghani

Nastaran Khodakarim

Ehsan Hejazi

Affiliations

Soon will be listed here.

Abstract

Objective: Preclinical evidences suggests that while fasting can reduce the side effects and toxicity of chemotherapy, it can make cancer cells more susceptible to chemotherapy. This study aimed to examine the effects of fasting mimicking diet (FMD) during neo-adjuvant chemotherapy in breast cancer (BC) patients.

Methods: Forty-four newly diagnosed human epidermal growth factor receptor 2-negative (HER2-negative) patients with BC were randomized equally into two groups (22 each), to receive either a fasting mimicking diet (FMD) or their regular diet for 3 days prior to and during neoadjuvant chemotherapy. This FMD was repeated every 3 weeks for 8 cycles. Efficacy, toxicity, hematologic, metabolic, and inflammatory parameters were measured and compared.

Results: The occurrence of grade III vomiting and neutropenia in the control group was significantly higher than the FMD group ( = <0.001 and = 0.04 respectively). Erythrocytes ( = 0.01) and neutrophils ( = 0.002) counts were significantly higher in FMD group compared to control group after cycle 8. There was a significant increase in median glucose and median insulin levels ( = 0.01 and = 0.005, respectively) in the control group between baseline and after cycle 8. While, the median Insulin-like growth factor-1 (IGF1) ( = 0.006) and hs-CRP ( = 0.02) levels were significantly decreased in the FMD group. At the end of study (after cycle 8), the median glucose level was significantly higher in control group ( = 0.008), while the median hs-CRP level was significantly lower in FMD group ( = 0.01). The Miller and Payne pathological response 4/5 (90-100% tumor cell loss) and the radiologically complete or partial response, as measured by MRI or ultrasound before surgery occurred more frequently in FMD group compared to the controls ( = 0.01).

Conclusion: Fasting mimicking diet was well tolerated during chemotherapy and reduced toxicity of chemotherapy and also, had beneficial effects of some metabolic parameters.

Clinical Trial Registration: https://irct.behdasht.gov.ir/user/trial/61386/view.

References

De Lorenzo M, Baljinnyam E, Vatner D, Abarzua P, Vatner S, Rabson A . Caloric restriction reduces growth of mammary tumors and metastases. Carcinogenesis. 2011; 32(9):1381-7. PMC: 3165123. DOI: 10.1093/carcin/bgr107. View

Hickish T, Astras G, Thomas P, Penfold S, Purandare L, Hickish T . Glucose intolerance during adjuvant chemotherapy for breast cancer. J Natl Cancer Inst. 2009; 101(7):537. DOI: 10.1093/jnci/djp025. View

Valdemarin F, Caffa I, Persia A, Cremonini A, Ferrando L, Tagliafico L . Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment. Cancers (Basel). 2021; 13(16). PMC: 8391327. DOI: 10.3390/cancers13164013. View

Dezfouli M, Moeinzadeh F, Taheri S, Feizi A . The Effect of Omega-3 Supplementation on Serum Levels of Inflammatory Biomarkers and Albumin in Hemodialysis Patients: A Systematic Review and Meta-analysis. J Ren Nutr. 2019; 30(3):182-188. DOI: 10.1053/j.jrn.2019.06.007. View

Xu Y, Gong M, Wang Y, Yang Y, Liu S, Zeng Q . Global trends and forecasts of breast cancer incidence and deaths. Sci Data. 2023; 10(1):334. PMC: 10224917. DOI: 10.1038/s41597-023-02253-5. View

Dorff T, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H . Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer. 2016; 16:360. PMC: 4901417. DOI: 10.1186/s12885-016-2370-6. View

Caffa I, Spagnolo V, Vernieri C, Valdemarin F, Becherini P, Wei M . Fasting-mimicking diet and hormone therapy induce breast cancer regression. Nature. 2020; 583(7817):620-624. PMC: 7881940. DOI: 10.1038/s41586-020-2502-7. View

de Groot S, Pijl H, van der Hoeven J, Kroep J . Effects of short-term fasting on cancer treatment. J Exp Clin Cancer Res. 2019; 38(1):209. PMC: 6530042. DOI: 10.1186/s13046-019-1189-9. View

de Groot S, Vreeswijk M, Welters M, Gravesteijn G, Boei J, Jochems A . The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. BMC Cancer. 2015; 15:652. PMC: 4595051. DOI: 10.1186/s12885-015-1663-5. View

10.

Wu Y, Wu T, Wu J, Zhao L, Li Q, Varghese Z . Chronic inflammation exacerbates glucose metabolism disorders in C57BL/6J mice fed with high-fat diet. J Endocrinol. 2013; 219(3):195-204. DOI: 10.1530/JOE-13-0160. View

11.

Ferroni P, Riondino S, Laudisi A, Portarena I, Formica V, Alessandroni J . Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression. Oncologist. 2016; 21(9):1041-9. PMC: 5016062. DOI: 10.1634/theoncologist.2015-0462. View

12.

Partridge A, Burstein H, Winer E . Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr. 2002; (30):135-42. DOI: 10.1093/oxfordjournals.jncimonographs.a003451. View

13.

de Groot S, Lugtenberg R, Cohen D, Welters M, Ehsan I, Vreeswijk M . Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nat Commun. 2020; 11(1):3083. PMC: 7311547. DOI: 10.1038/s41467-020-16138-3. View

14.

Charehbili A, van de Ven S, Smit V, Meershoek-Klein Kranenbarg E, Hamdy N, Putter H . Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). Ann Oncol. 2014; 25(5):998-1004. DOI: 10.1093/annonc/mdu102. View

15.

Di Biase S, Longo V . Fasting-induced differential stress sensitization in cancer treatment. Mol Cell Oncol. 2016; 3(3):e1117701. PMC: 4909408. DOI: 10.1080/23723556.2015.1117701. View

16.

Ogston K, Miller I, Payne S, Hutcheon A, Sarkar T, Smith I . A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003; 12(5):320-7. DOI: 10.1016/s0960-9776(03)00106-1. View

17.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

18.

Laplante M, Sabatini D . mTOR signaling in growth control and disease. Cell. 2012; 149(2):274-93. PMC: 3331679. DOI: 10.1016/j.cell.2012.03.017. View

19.

Withers S, Kass P, Rodriguez Jr C, Skorupski K, OBrien D, Guerrero T . Fasting Reduces the Incidence of Delayed-Type Vomiting Associated with Doxorubicin Treatment in Dogs with Lymphoma. Transl Oncol. 2014; . PMC: 4145391. DOI: 10.1016/j.tranon.2014.04.014. View

20.

Zorn S, Ehret J, Schauble R, Rautenberg B, Ihorst G, Bertz H . Impact of modified short-term fasting and its combination with a fasting supportive diet during chemotherapy on the incidence and severity of chemotherapy-induced toxicities in cancer patients - a controlled cross-over pilot study. BMC Cancer. 2020; 20(1):578. PMC: 7310229. DOI: 10.1186/s12885-020-07041-7. View